Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Passage Bio, Inc. PASG
$1.01
+$0.01 (1.00%)
На 18:02, 12 мая 2023
+494.06%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
56265501.00000000
-
week52high
2.89
-
week52low
0.95
-
Revenue
0
-
P/E TTM
0
-
Beta
0.99004900
-
EPS
-2.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 17 мая 2022 г. |
| Citigroup | Buy | Buy | 17 мая 2022 г. |
| JP Morgan | Neutral | Overweight | 08 мар 2022 г. |
| Raymond James | Outperform | Outperform | 04 мар 2022 г. |
| Goldman Sachs | Neutral | Buy | 19 янв 2022 г. |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| Citigroup | Buy | Buy | 11 ноя 2022 г. |
| Canaccord Genuity | Buy | 08 ноя 2022 г. | |
| Chardan Capital | Buy | Buy | 15 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kapadia Sandip | D | 0 | 5000 | 01 дек 2022 г. |
| Fotopoulos Alexandros | D | 37500 | 12500 | 22 ноя 2022 г. |
| Fotopoulos Alexandros | D | 20245 | 3720 | 22 ноя 2022 г. |
| Fotopoulos Alexandros | A | 23965 | 12500 | 22 ноя 2022 г. |
| Fotopoulos Alexandros | A | 50000 | 50000 | 10 ноя 2022 г. |
| Cale Edgar B. | A | 50000 | 50000 | 10 ноя 2022 г. |
| Forman Mark S | A | 50000 | 50000 | 10 ноя 2022 г. |
| King Simona | A | 50000 | 50000 | 10 ноя 2022 г. |
| Chou William | A | 885000 | 885000 | 10 окт 2022 г. |
| Toernsen Monika Maria | D | 3319 | 1681 | 19 сент 2022 г. |
Новостная лента
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
GlobeNewsWire
03 ноя 2022 г. в 07:30
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 10, 2022, to report its third quarter 2022 financial results and discuss recent business updates.
Passage Bio to Present at Chardan's 6th Annual Genetic Medicines Conference
GlobeNewsWire
26 сент 2022 г. в 07:00
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will present at the upcoming Chardan Genetic Medicines Conference being held from October 3-4, 2022 in New York City.
Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
06 авг 2022 г. в 10:50
Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona King - CFO Mark Forman - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen Neena Bitritto-Garg - Citi Alex Nackenoff - Raymond James Laura Chico - Wedbush Operator Good morning and welcome to the Passage Bio Second Quarter 2022 Financial and Operating Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company's request.
Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
GlobeNewsWire
05 авг 2022 г. в 07:00
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a virtual panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.
Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
GlobeNewsWire
28 июл 2022 г. в 07:30
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights.